Navigation Links
Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups

CHAPEL HILL, N.C., March 11 /PRNewswire/ -- With patent expiration a looming concern across the bio-pharmaceutical industry, new product commercialization efforts have taken on increased importance. It's against this backdrop that new product planning groups across biopharma are trying to deal more effectively with the twin pressures of meeting timelines and delivering commercial insights.

A recent data-rich benchmarking study from Best Practices, LLC delivers actionable insights on the critical elements of the new product planning (NPP) function. The study, "Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability," identifies the full set of activities that NPP groups perform across the development cycle as well as the structure and roles of NPP groups.

To download a complimentary study excerpt, go to:

The research project illustrated that as companies move through each successive development Phase, the actual nature of assessment activities changes. For instance, many companies stated that competitive assessments and lifecycle planning made in the early stages are somewhat speculative, primarily designed to spot opportunities. Later on these activities become more specific, designed to drive forecasts.

While most companies perform competitive assessments from pre-clinical all the way through Phase 3, study participants said the activity is particularly critical in pre-clinical because:

  • It can gauge what changes will occur in the years ahead
  • It helps with understanding the disease state and where competitors' products fit in
  • It informs how well your drug will fit in the market
  • It helps frame "go, no-go" analysis so that, as data comes in, competitive assessment can drive forecasting and profitability potential
  • The research examines dozens of NPP developmental activities in terms of timing during the development process, intended outcomes and value for the organization.

In addition, the study details the strengths and weaknesses of various NPP organizational structures and how the operational characteristics of the NPP function evolve as a company matures.

To review samples of key metrics and findings in the report, download a complimentary study excerpt at:

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 pharma companies across the globe contributed data. In-depth interviews were conducted with leaders from 13 of the participating companies. The research report reflects the current state of New Product Planning efforts at best-in-class organizations such as Abbott, Astellas, Bayer, Daiichi Sankyo, Eli Lilly, Merck, Novartis, sanofi aventis, Wyeth and others.

To learn more about Best Practices' other timely research visit: or contact Jeff Zimmer at 919-767-9180 or


Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. 

SOURCE Best Practices, LLC

Back to top



SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AdMeTech Hails New Research That Shows Promise of MRI to Discriminate Aggressive Prostate Cancer From Dormant Disease
2. Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology
3. Americas Pharmaceutical Research and Biotechnology Companies Lead the Charge Toward Longer, Healthier Lives for Americans
4. AdMeTech Calls for Major Research Commitment to End Prostate Cancer Crisis
5. Researchers Pave Way for Tracking of Prostate Motion With a Single kV Imager During Arc Radiotherapy
6. BNA Books Announces Publication of New 2009 Cumulative Supplement to Pharmaceutical Law: Regulation of Research, Development, and Marketing
7. New Research from Best Practices, LLC Helps Medical Device Companies Earn the Highest Profit Possible During Their Products Patent Lifecycle
8. AdMeTech to Testify in Congress About Prostate Cancer Crisis, Research to Improve Diagnostic Tools as a Solution
9. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
10. Biomedical Advanced Research and Development Authority (BARDA) Project for Radiation Exposure Research Awarded to SRI International
11. As Biopharma Companies Reshape Sales Model, Most See Resetting Territory Size and Implementing Individualized Call Plans as First Steps Toward Change, According to New Research From Best Practices, LLC
Post Your Comments:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
Breaking Medicine News(10 mins):